|
Clinical Trials for Lymphoma |
|
|
|
Preclinical evaluation of a novel synthetic antibody for treatment of spontaneously occurring B-cell lymphoma in dogs.
Eligibility Requirements
• The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous treatment, and relapsed patients that may have failed other treatment options.
• All dogs must be examined by a VMTH oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial: Confirmed diagnosis; Physical examination with weight recorded; CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Study Objective
It is possible that treatment with SH 7139 will be an effective therapy for your dog’s lymphoma, and may result in remission. It is hoped that with the information obtained from this trial, SH 7139 can proceed to clinical trials in people with non-Hodgkin’s lymphoma.
Compensation
Dog owners participating in this study will be given special financial considerations. This is a fully funded trial, once the patient is determined eligible by the oncologist. The study will pay for the cost of the weekly exam fees, bloodwork, anti-body drug. Please click on the link for more details.
Location of Trial
Davis, CA
More information
Novel Product Targeting Canine B-Cell and T-Cell Lymphoma
Eligibility Requirements
• The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma or T-Cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous treatment, and first relapsed.
Study Objective
Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and ages. Lymphoma is a devastating disease that, when left untreated, will lead to death in weeks. There is no cure known to this disease. Current treatments involve the use of extensive chemotherapy and / or radiotherapy, resulting generally in an initial response followed by relapse, and eventually resistance. Further, these treatments may be associated with severe side effects affecting patient’s quality of life. Therefore, a more effective and safe treatment for canine lymphoma is urgently needed. New treatments based on the use of tumor targeting Product (non-chemotherapeutic agents) have been developed and used for the treatment of lymphoma in humans achieving an improved treatment efficacy with survival extension and an improved quality of life while significantly reducing toxicity. These treatments have proven to be groundbreaking for humans. This Product is designed specifically for dogs. This Product was shown to be safe in normal dogs and effective at depleting lymphoma cells in laboratory studies. This study proposes the use of this Product to obtain additional data about its safety and its Pharmacokinetic and Pharmacodynamic properties in dogs with lymphoma.
Compensation
Dog owners participating in this study will be given special financial considerations. The study will pay for the cost of the Product, which is not available anywhere outside the study, and will also cover for the cost of examination and blood work required by the study protocol after enrollment. Please click on the link for more details.
Location of Trial
Davis, CA
More information
Evaluation of NBD Peptide as an Adjunct Therapy for the Treatment of Non-Hodgkin Lymphoma
Eligibility Requirements
Your dog is eligible to participate in this clinical trial if:
• they have been diagnosed with diffuse large B-cell lymphoma;
• they have relapsed with the disease OR are newly diagnosed;
• If the dog is relapsed, they have not received chemotherapy at least 3 weeks prior to screening. If newly diagnosed, they have not yet received any chemotherapy treatment;
• they have NOT received prednisone or other systemic steroids within the past three weeks;
• they are otherwise healthy with no major organ disease;
• they have evidence of an active NF-kappaB pathway within their malignant lymph node (to be determined at screening visit)
Study Objective
Lymphoma is a cancer of white blood cells that occurs commonly in dogs. Chemotherapy is used to treat lymphoma and about 85% of dogs respond well to this treatment. However, the majority of dogs will relapse with clinical disease within one year of diagnosis and treatment. One potential reason for disease recurrence is the presence of drug resistant lymphoma cells that are not killed by chemotherapy. Researchers at Penn Vet have identified an aberrantly active, intracellular pathway within lymphoma cells that promotes cancer cell survival and proliferation. Results of a pilot clinical trial have shown that blocking this pathway using a drug known as NBD peptide can promote cancerous cell death.
This clinical trial expands on our previous pilot study and aims to determine whether NBD peptide can inhibit aberrant pathway activity and kill cancer cells in dogs with B-cell lymphoma improve short and long term outcomes in dogs with lymphoma.
Compensation
There is no fee to participate in this study. All study procedures (including blood work and lymphoma immunophenotyping) plus study medication (NBD peptide and antibiotics) will be provided at no cost. The study will pay for a single dose of standard chemotherapy. The potential benefits could include increased responsiveness to chemotherapy leading to remission and prolonged remission times in patients receiving the NBD peptide Please click on the link for more details.
Location of Trial
Philidelphia, PA
More information
Ablation of Tumor Initiating Cells by P-glycoprotein Inhibition - A Study in Canine Diffuse Large B Cell Lymphoma
Eligibility Requirements
Your dog is eligible to participate in this clinical trial if:
• they have been recently diagnosed with diffuse large B-cell lymphoma;
• they have not received chemotherapy for the treatment of lymphoma;
• they weigh between 30 and 88 pounds (40 kg);
• they are otherwise healthy with no major organ disease;
• they have not received prednisone or any other systemic steroids
Study Objective
Lymphoma is a cancer of white blood cells that occurs commonly in dogs. Chemotherapy is used to treat lymphoma and about 85% of dogs respond well to this treatment. However, the majority of dogs will relapse with clinical disease within one year of diagnosis and treatment. One potential reason for disease recurrence is the presence of drug resistant lymphoma cells that are not killed by chemotherapy.
This clinical trial aims to determine whether a drug known as PSC-833 can reduce or eliminate drug-resistant lymphoma cells when used in combination with standard chemotherapy improve short and long term outcomes for dogs with lymphoma. In previous studies, PSC-833 was well tolerated in dogs with minimal toxicity. PSC-833 is an oral drug given once a day for 5 days and will be combined in this study with doxorubicin chemotherapy.
Compensation
There is no fee to participate in this study. All study procedures and medication will be provided at no cost. The client's account at Penn Vet will be credited $2,500 for continued chemotherapy and cancer care once the study is completed. Please click on the link for more details.
Location of Trial
Philidelphia, PA
More information
Liposomal clodronate to augment tumor vaccine responses in a canine model of non-Hodgkin lymphoma.
Eligibility Requirements
• Dogs with a confirmed diagnosis of stage IIIa or Iva, B-cell lymphoma are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible, including bloodwork (complete blood count and chemistry profile), thoracic radiographs, and flow cytometry to confirm B-cell immunophenotype. They must have good function of liver and kidneys, have acceptable blood cell counts, and are free of severe underlying disease. No prior chemotherapy for lymphoma is permitted, and a 14-day washout period from corticosteroids is required
Study Objective
Mouse studies indicate that depletion of vaccine-elicited myeloid cells (VEMC) using liposomal clodronate administered at the time of vaccination can significantly enhance tumor vaccine responses in mouse lymphoma models. We have previously extensively evaluated liposomal clodronate as an antitumor drug in dogs with other types of cancer (soft tissue sarcoma and malignant histiocytosis). We have also previously formulated autologous cancer vaccines and administered them to dogs with lymphoma, melanoma and hemangiosarcoma, using a vaccine adjuvant developed in our laboratory. We are now proposing to evaluate a combined tumor vaccine and VEMC depletion approach in dogs with B cell lymphoma, as a model for human non-Hodgkin lymphoma. The goals of this study are to determine whether co-administration of liposomal clodronate (LC) significantly improves immune responses to a novel autologous lymphoma vaccine in dogs with B cell lymphoma, and to determine whether effective vaccine responses can be generated in dogs undergoing concurrent chemotherapy for B cell lymphoma
Compensation
The owner is responsible for the cost of diagnosing and staging the dog’s lymphoma prior to entering the study. Owners are expected to make and keep all appointments according to the study protocol, and must be committed to completing the entire study protocol and follow-up examinations. Clients participating in this study will be given special financial considerations. Specifically, the study will cover the costs of the lymph node removal, recheck examinations, complete blood counts, and costs of chemotherapy (drug and administration fees). The owner will be responsible for the costs of the initial examination, tests to insure eligibility to participate, and any ancillary medications.The costs of treating any side effects related to chemotherapy will also be the owner’s responsibility. Please contact NCI for further information.
Location of Trial
Fort Collins, CO
More information
Study NA Pilot Study to Assess Feasibility of Tissue Collections and Molecular Profiling for future Comparative Oncology Personalized Medicine
Eligibility Requirements
One of the following:
• Scottish terriers with transitional cell carcinoma of the bladder
• Golden retrievers with multi-centric lymphoma
• American cocker spaniels with oral melanoma
• creatinine > 3.0
• bilirubin > 2.0 or elevated bile acids
• HCT < 25%, platelets < 50,000
• any >grade 2 hematologic/biochemical abnormality
Study Objective
A pilot study in pet dogs with cancer is needed to determine the feasibility of tissue collection, clinical utility, and large-scale target interrogation across a multi-institutional setting. Data from this feasibility study will inform the design of a personalized therapeutic intent trial in pet dogs. Future comparative oncology modeling of novel personalized medicine strategies will hopefully progress the field and translate into more efficient targeted therapy prescriptions for human cancer patients.
Compensation
Please contact NCI for further information.
Location of Trial
Colorado State University
Purdue University
Tufts University
University of California at Davis
University of Florida
University of Georgia
University of Guelph
University of Michigan
University of Pennsylvania
University of Tennessee
University of Wisconsin
More information
Bcl-2 Canine Lymphoma Study
Eligibility Requirements
• B Cell lymphoma confirmed by histopathology
• Complete tumor staging including: CBC, chemistry panel, UA, thoracic radiographs, abdominal radiographs+ US, bone marrow aspirate and lymph node biopsy.
• Life expectancy of > 12 weeks, NO previous chemo other than prednisone for < 2 weeks. Adequate renal, hepatic and hematopoietic perimeters.
• Exclusion criteria: hypercalcemia and mediastinal lymph node involvement.
Study Objective
Bcl-2 Canine Lymphoma Study is an imaging study that involves injection of a radioisotope (indium) to detect the presence of the bcl-2 gene product inside tumor cells of canines with B cell lymphoma. Patients will receive three separate scans…one at enrollment; another after the patient has been in a durable remission (6-8 week range) and one at relapse. All dogs participating in this study will be placed on the University of Wisconsin-Madison lymphoma protocol. This 25 week protocol is considered the gold standard for treating canine lymphoma.
Compensation
• All nuclear medicine scan cost are covered by the study.
• $1000.00 credit toward cost of chemotherapy drugs
• Initial workup is owner’s responsibility.
Please click on the link for more details.
Location of Trial
Colombia, MO
More information
AD-198 Canine Refractory Lymphoma Study
Eligibility Requirements
• Must have 3 week period since last chemo.
• Current use of prednisone ok.
• Adequate renal, hepatic and hematologic parameters.
• CBC, chemistry panel, UA, FNA and measurement of lymph nodes at presentation.
Study Objective
AD-198 Canine Refractory Lymphoma Study will assess the tolerability and efficacy of AD-198 a novel chemotherapeutic agent in refractory lymphoma patients. Patients will receive an intravenous infusion of AD-198 every three weeks, if they respond to therapy.
Compensation
Free drug Initial workup, chemo administration and blood work, office calls, etc. are owner’s responsibility. Please click on the link for more details.
Location of Trial
Colombia, MO
More information
Echocardiographic and Total Body Water Evaluation of Canine Lymphoma
Eligibility Requirements
• Newly diagnosed lymphoma
• Patient must weigh over 20 kg.
• Dogs with elevated calcium, advanced kidney or heart disease are ineligible
• Enrollment will be one-two weeks after first chemotherapy treatment.
• Dogs must be fasted for 12 hours prior to the study. Water ok.
Study Objective
The purpose of this study is to determine the prevalence of dehydration in dogs with lymphoma, and improve recognition of the echocardiographic changes caused by dehydration.
Compensation
Free echocardiogram and cardiology consultation. Most patients will have an additional follow-up echocardiogram, which will also be covered by the study. Please click on the link for more details.
Location of Trial
Colombia, MO
More information
CCB02. The National Cancer Institute and UCDAVIS
Eligibility Requirements
• Confirmed diagnosis
• Physical examination with weight recorded
Study Objective
The National Cancer Institute is looking for Golden Retrievers with Lymphoma, Osteosarcoma, Mast Cell Tumors, and Hemangiosarcoma to participate in a clinical trial
Compensation
If your Golden Retriever is eligible for any of the above mentioned cancer types, the study will pay for full-staging (CBC, Chemistry panel, Urine Analysis, Ultrasound, Radiographs) $800-$1000 of staging. This is not a therapy, chemo or drug study. It is a tissue collection study to populate the tissue bank for future research. After your pets surgery you will be instructed to follow-up with an oncologist or your local veterinarian for follow-up care. Please click on the link for more details.
Location of Trial
Davis , CA
More information
Preclinical Comparison of Three Indenoisoquinolines Candidates in Tumor Bearing Dogs
Eligibility Requirements
• histologically confirmed lymphoma
• measurable disease that is amenable to biopsy •
• favorable performance status •
• both newly diagnosed dogs and those with recurrent/relapse disease are eligible
• No significant co-morbid illness, which includes but is not limited to renal or hepatic failure, history of congestive heart failure or clinical coagulopathy
• creatinine > 3.0 • bilirubin > 2.0 or elevated bile acids
• HCT < 25%, platelets < 50,000
• any >grade 2 hematologic/biochemical abnormality
Study Objective
This clinical trial sponsored by the National Cancer Institute (NCI) assesses the safety and effectiveness of three indenoisoquinolines when given to dogs with lymphoma. Results of this trial will directly inform the development efforts these candidates in human clinical trials.
Compensation
To be determined. Please click on the link for more details.
Location of Trial
To be determined
More information
Lymph node biopsy to evaluate tumor-infiltrating lymphocytes in dogs with lymphoma.
Eligibility Requirements
• Certain criteria determine patient eligibility. Canine patients with suspected B cell lymphoma are eligible for inclusion in this study. Patients may NOT have received previous chemotherapy for the treatment of their disease. Previous steroid treatment is accepted with a 7-day washout period. Patients should be in relatively good health.
Study Objective
We are investigating whether T lymphocytes (a type of lymphocyte that is very important in helping the body fight off cancer) could be used to help generate a powerful vaccine for the treatment of B cell lymphoma. Our lab’s previous research in mice has shown that stimulating T lymphocytes with mimotope vaccines—lab-created mimics of tumor molecules - causes T cells to respond aggressively against tumors and inhibits tumor growth. To determine whether we can generate similarly successful vaccines for dogs we first need to determine the quantity and quality of the T lymphocytes present within the lymph node of dogs with B cell lymphoma.
This will be done by harvesting a small portion of the lymph node collected from your dog at the time of surgical lymph node removal (excisional biopsy). We will then analyze this sample for particular characteristics of T lymphocytes to determine if the T cells could potentially be used to design an effective anti-cancer vaccine. We will also collect a small blood sample for lymphocyte analysis. We would also like to investigate whether certain T cell characteristics in either the blood or the lymph node are associated with outcome in dogs with lymphoma.
Compensation
Clients participating in this study will be given special financial considerations. The costs of lymph node excision, general anesthesia, histopathology and immunophenotyping will be covered by the study. Alternatively, if your dog is also participating in the CCOGC tissue archiving study, you will instead receive a $550.00 credit that can be applied to the cost of future diagnostics and/or treatments at the VTH. Please click on the link for more details.
Location of Trial
Fort Collins, CO
More information
DOGS WITH T-CELL LYMPHOMA
Eligibility Requirements
• Confirmed T-cell lymphoma
Study Objective
Lymphoma is one of the most common cancers in dogs. Most affected dogs present with enlarged lymph nodes. While lymphoma is responsive to chemotherapy, with more than 80% of dogs achieving complete clinical remission of more than one year, the type of cell involved (T-cell or B-cell) affects prognosis. Dogs with T-cell lymphoma have a poorer prognosis as these cells are more resistant to chemotherapy and remission times are shorter than for dogs with B-cell involvement. Recent laboratory observations suggest that the tyrosine kinase inhibitor, masitinib may enhance the anti-tumor activity of chemotherapeutic agents. Patients will be randomized to receive either masitinib alone, doxorubicin alone, or a combination of these agents.
Compensation
The cost of masitinib and doxorubicin will be paid for by the study. Owners are responsible for the cost of the initial staging, blood and urine tests, and examination fees. Please click on the link for more details.
Location of Trial
Madison, WI
More information
Malignant Lymphoma
Eligibility Requirements
• Dogs will be eligible for the clinicaltrial if they have a biopsy diagnosis of multicentric lymphoma.
• Received no priorchemotherapy or radiation therapy treatment within the past 30 days.
• They must also nothave received previous treatment with prednisone or other steroid drugs such as dexamethasone or Depo-medrol within the past 30 days.
Study Objective
The purpose of this clinical trial is to assess the importance of prednisone in a combination chemotherapy protocol (UW-25) for canine lymphoma. Dogs entering into this trial will be randomly assigned to receive either the standard UW-25 protocol (the current standard of care for canine lymphoma that does include prednisone) or a modified UW-25 protocol that does not include prednisone.
Compensation
Financial benefit will be provided for owners of dogs enrolling in the clinical trial. The treatment for dogs in the trial will cost approximately 10% less than it would otherwise. For instance, if treating your dog would normally cost $5000, a discount of approximately $500 will be applied to your dog’s treatment. Please click on the link for more details.
Location of Trial
West Lafayette, IN
More information
Dr. Michael Childress at (765) 494-1107, mochildr@purdue.edu, or you may contact Sarah Lahrman at (765) 496-6289, salahrma@purdue.edu.
PCR and Real-Time PCR for Analysis of PARR in Dogs with Lymphoma
Eligibility Requirements
• The study will include dogs with a confirmed diagnosis of multicentric lymphoma (cytology or histology) with owner consent and intent to treat with a standard chemotherapy protocol . These dogs must be clinically staged with at least a complete blood/platelet count, chemistry profile, and urinalysis. Additional clinical staging including thoracic radiographs, abdominal ultrasound, and bone marrow aspirate (if complete blood count is abnormal) is recommended as optimal routine cancer care, but is not required for proceeding with treatment or enrollment in the study.
Exclusion Criteria
• Patients weighing 2kg or less.
Study Objective
The purpose of this study is to evaluate whether molecular tools (PCR and RT-PCR) can be used to detect microscopic amounts of cancer cells remaining in the lymph nodes after treatment and whether this predicts the duration of remission.
Compensation
Free immunophenotyping (to determine whether a dog has B-cell or T-cell lymphoma at the time of diagnosis) which will help to guide more specific chemotherapy treatment regimen. Please click on the link for more details.
Location of Trial
North Grafton, MA
More information
Determination of ABCB1 (MDR1) Expression in Relapsed Lymphoma
Eligibility Requirements
• Dogs with multicentric lymphoma initiating chemotherapy with a CHOP-based protocol.
Exclusion Criteria
• Dogs with other significant medical conditions or previously treated with CHOP drugs.
Study Objective
The goal of this study is to determine by real-time PCR whether increased expression of ABCB1 contributes to the development of chemoresistance.
Compensation
This study covers the cost associated with lymph node sample collection and RT-PCR analysis. Please click on the link for more details.
Location of Trial
North Grafton, MA
More information
P.A.G.
Eligibility Requirements
• Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial.
• Confirmed diagnosis of lymphoma or oral malignant melanoma
• Physical examination with weight recorded
• CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
• Baseline Evaluation for Eligibility
• Histologically or cytologically confirmed disease
• Measurable and biopsiable tumor
• Ability to stay overnight
• Dog has to be greater than 10k
• Informed owner consent
Study Objective
The goal of this study is to evaluate the efficacy of using the enzyme Pegylated Arginine Deiminase (non-chemotherapy drug) as a subcutaneous injection.
Compensation
This study is fully funded. Please contact the Oncology department for more information. This is a Phase I study.
Please click on link for more details.
Location of Trial
Davis, CA
More information
Liposomal clodronate in canine cancer (excluding mast cell tumor, hemangiosarcoma and malignant histiocytosis)
Eligibility Requirements
• Dogs with biopsy-confirmed cancers (excluding mast cell tumor, hemangiosarcom and malignant histiocytosis) are potentially eligible
• The tumor must be less than 8cm (approximately 3.5 inches) in diameter and located in an easily accessible area for biopsy.
• Dogs must have good function of liver and kidneys and acceptable blood cell counts.
• Dogs must be free of underlying disease.
• OWNERS MUST CONSENT TO A POSTMORTEM EXAM (AUTOPSY) AT THE TIME THEIR PET DIES OR IS EUTHANIZED.
Study Objective
The goals of this study are to demonstrate liposomal clodronate as a safe and effective cancer therapy and to determine the anti-tumor activity of liposomal clodronate against a variety of canine tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Fort Collins, CO
More information
Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog
Eligibility Requirements
• Any dog weighing over 35 lbs that has been newly diagnosed with Lymphoma and is undergoing a blood draw procedure for diagnostic purposes. Additionally, healthy normal dog volunteers weighing over 35 lbs will be asked to donate a sample as well.
• Dogs with significant concurrent disease are excluded from this study.
Study Objective
Not listed on website.
Compensation
Immunophenotyping (determination of the type of lymphoma using special stains) will be done free of charge for all dogs with Lymphoma entering the study. There will be no financial incentive for normal dogs entering the study. Each lymphoma dog will participate on a two time basis (once before chemotherapy and then 7 days post chemotherapy at the time of CBC collection). Normal dogs will participate on a one time basis only. No follow up is necessary. Please click on link for more details.
Location of Trial
College Station, Texas
More information
Histiologic and cytogenic analysis canine lymphoma
Eligibility Requirements
• Dogs with newly diagnosed multicentric lymphoma that have enlarged peripheral lymph nodes.
• Dogs that have received previous chemotherapy are NOT eligible
Study Objective
The goal of this study is to correlate the different histologic subtypes of canine lymphoma with gene expression and response to treatment and survival times.
Compensation
This study is partially funded. Please click on the link for more details.
Location of Trial
North Grafton, MA
More information
Body condition in canine lymphoma
Eligibility Requirements
• Dogs with multicentric lymphoma that have undergone full staging.
• Prior chemotherapy (including prednisone) or dogs with lymphoma within the gastrointestinal tract are NOT eligible
Study Objective
The goal of this study is to document how often dogs experience weight loss or decrease in muscle mass at the time that lymphoma is diagnosed, and whether this finding impacts how dogs respond to treatment.
Compensation
This study is not funded. Please click on link for more details.
Location of Trial
North Grafton, MA
More information
High-Dose cyclophasphamide for canine lymphoma
Eligibility Requirements
• Dogs must have a multicentric lymphoma in complete remission after multiagent CHOP-based inducation chemotherapy
• Dogs with other significant medical conditions or with lower urinary tract diseases are NOT eligible to participate in this study
Study Objective
The goal of this study is to determine the highest dose of cyclophosphamide that can be given safely with cytokine support and whether this treatment will prolong remission duration beyond standard chemotherapy protocols.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
North Grafton, MA
More information
Activated autologous T cell killing CD20+ B cell lymphoma in the dog
Eligibility Requirements
• Dogs must weigh over 35 lbs
• Dogs must be newly diagnosed with lymphoma
• Dogs must not have significant concurrent disease
Study Objective
No objective was listed on the website. The study is using a vaccine containing a melanoma antigen that could induce an antibody response in dogs. They have also shown that the vaccine could stimulate peripheral blood natural killer cells to kill melanoma target cells in a laboratory test.
Compensation
Immunophenotyping (determination of the type of lymphoma using special stains) will be done free of charge for all dogs with lymphoma entering the study. Please click link for more details.
Location of Trial
College Station, TX
More information
Canine comparative oncology and genetics consortium (CCOGC) tissue bank for dogs with lymphoma who have not been previously treated
Eligibility Requirements
• Dogs must have diagnosis of lymphoma
• Dogs CANNOT have had any prior treatment
• Dogs must have a surgically accessible lymph node and be healthy enough to tolerate anesthetic and surgical procedure associated with lymph node removal.
Study Objective
The purpose of this study is to help populate a national tumor bank or archive. The primary mission of the CCOGC is to improve the diagnosis and treatment of cancer and other diseases in dogs. There may also be benefits to human patients diagnosed with similar types of cancers. The collective information from several thousand tissue samples from dogs will contribute important knowledge about our understanding of cancer, its prevention early diagnosis and treatment.
Compensation
This study is partially funded. Please click link for more details..
Location of Trial
Fort Collins, CO
More information
LLP2A with Taxol
Eligibility Requirements
• Dogs with high-grade non-Hodgkin’s lymphoma and measurable disease that have failed standard therapy and/or whose owners decline standard therapy
Study Objective
This is a Phase I trial looking at two novel therapeutic approaches and is designed to test a new targeted therapy for lymphoma in dogs. This is an experimental therapy and the goals of the study are to find a safe and tolerable dose and document any toxicity seen with its use.
Compensation
If eligibility requirements are met and approved by your oncologist, the study is fully funded. Additionally, the study covers for up to $1000 if an adverse event should occur. All treatment must be done at the UC Davis Veterinarian Teaching Hospital.
Location of Trial
Davis, CA
More information
Nanoparticle taxol for the treatment of dogs with relapsed lymphoma
Eligibility Requirements
• Dogs with histologically or cytologically confirmed relapsed lymphoma
• Dogs with at least one measurable affected lymph node that can be aspirated
Study Objective
As this is a Phase I trial, the primary endpoint of this study will be to find a safe, pharmacokinetically and pharmacodynamically relevant dose.
Compensation
This is a fully funded study with $1000/per adverse event
Location of Trial
Davis, CA
More information
Cerenia for nausea during administration of DTIC in dogs
Eligibility Requirements
• Any dog receiving DTIC as part of their cancer therapy
Study Objective
The goal of this study is to evaluate the efficacy of an established anti-nausea medication, Cerenia, in controlling emesis developing from DTIC administration.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
North Grafton, MA
More information
Canine patients with osteosarcoma, lymphoma, or oral malignant melanoma, mast cell tumors, soft tissue sarcomas/histiocytic sarcoma/malignant histiocytosis, primary pulmonary cancer, hemangiosarcomas
Eligibility Requirements
• Requirements vary for each type of cancer listed above. Please click on link for more details.
Study Objective
The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Davis, CA: More information
North Grafton, MA: More information
Madison, WI: More information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
|
| |
|
